Daniel Vasella Quotations

Based on the robust results, we are are confident of achieving our full-year objectives for new record sales and earnings.

It is a hypothetical question. I don't answer hypothetical questions.

Our increased level of investment in marketing and sales, with the priority on key growth drivers, resulted in a sales growth of 21 percent in Pharmaceuticals in the U.S.,

Our plan is to turn around the Chiron vaccines business, which will require investments in research and development, and manufacturing, to increase quality and capacity, so that we can better meet customer demand and address public health needs,

Our plan is to turn around the Chiron vaccines business,

Looking ahead, we anticipate a somewhat softer third quarter and, again, a more dynamic fourth quarter resulting in mid-single-digit sales growth... and solid operating growth for the full year,

Market growth in 2006 will slow down somewhat. I expect that we will be able to continue to gain market share.

Litigation is potentially much larger when you vaccinate healthy people.

We are confident of delivering in 2006 another year of dynamic growth with record sales and earnings.

We are entering an exciting field with vaccines. Chiron has a fair share of challenges but I believe we can help them in solving those.

We first want to fix the quality and quantity problems which are at hand.

At present, no collaboration has been discussed with Roche management, although we hope that over time we will be able to explore areas of collaboration.

If you can't find the human resources in Europe you go elsewhere. As a European, I'm concerned for Europe.

I am pleased with the overall strong performance of our business in the third quarter, particularly the dynamic growth of Pharmaceuticals.